After a phase I trial showed manageable toxicity, a phase II randomized double blind trial with advanced KRAS-mutated NSCLC recruited 87 patients and randomized them to receive either docetaxel with selumetinib or docetaxel with placebo [71]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.